publication venue for
- The Feasibility of 64Cu-PSMA I&T PET for Prostate Cancer.. 37. 2021
- A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles.. 35. 2020
- Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer.. 30. 2015
- Compton scattering by internal shields based on melanin-containing mushrooms provides protection of gastrointestinal tract from ionizing radiation.. 27. 2012
- Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.. 25. 2010
- Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.. 24. 2009
- Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.. 24. 2009
- Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease.. 21. 2006
- Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.. 20. 2005
- Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?. 19. 2004
- Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.. 15. 2000
- Preparation and in vitro studies of [125I]IUDR-T101 antibody conjugate.. 14. 1999
- Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters.. 13. 1998
- Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. 2000
- Granulocyte colony stimulating factor (G-CSF): biology and clinical status. 1996